Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23844141 | 0.90 | BTN3A1 (0.36) | BTN3A1RIPK1 | |
| SCHEMBL23813356 | 0.80 | BTN3A1 (0.31) | BTN3A1RIPK1 | |
| SCHEMBL23844005 | 0.80 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL25012534 | 0.80 | BTN3A1 (0.33) | BTN3A1RIPK1 | |
| SCHEMBL27437052 | 0.79 | BTN3A1 (0.35) | BTN3A1RIPK1 | |
| SCHEMBL27045976 | 0.78 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL19223224 | 0.78 | BTN3A1 (0.35) | BTN3A1RIPK1 | |
| SCHEMBL25012702 | 0.77 | BTN3A1 (0.33) | BTN3A1 | |
| SCHEMBL23819279 | 0.77 | BTN3A1 (0.37) | BTN3A1RIPK1 | |
| SCHEMBL23844009 | 0.77 | BTN3A1 (0.34) | BTN3A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | BTN3A1 4438/4885RIPK1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.